To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure

Open Label, Randomized, Active Drug Comparative, Parallel Group, Multi-center, Phase IV Study to Compare and Evaluate the Efficacy and Safety of Candemore Tab and Atacand Tab.

To compare and evaluate the efficacy and safety of Candemore tab. versus Atacand tab. on blood pressure in patients with hypertension diagnosed congestive heart failure

This is an open label, randomized, active drug comparative, Parallel group, Multi-center, phase IV study. Patients receive candemore tablet or atacand tablet. Initial dose is 4mg/day or 8mg/day. Every 2 weeks, patients take double dose if patients blood pressure is measured SBP ≥ 100mmHg and DBP > 60mmHg. Maximum dose is 16mg/day.

Inclusion Criteria:

• willing and able to provide written informed consent
• age 20 years or older
• patient with congestive heart failure, taking treatment medicine and NYHA grade II~III
• patient with hypertension, taking treatment medicine or SBP ≥ 140mmHg or DBP ≥ 90mmHg at the screening visit

Exclusion Criteria:

• Known or suspected secondary hypertension(ex. aortic coactation, primary hyperaldosteronism, renal artery stenosis, pheochromocytoma, cushing syndrome, polycystic renal disease)
• blood creatinine level ≥ 2.5mg/dl
• blood potassium level > 5.5mEq/L
• blood SGOT, SGPT level ≥ maximum normal range X3 or patient with sever hepatic dysfunction, cholestasis
• pregnant or breast-feeding
• premenopausal women not using adequate contraception
• patient has history about hypersensitivity or taboo of investigational product
• patient with lactose intolerance or Lapp lactase deficiency or glucode-galactose malabsorption
• administration of other study drugs within 1 month prior to screening
• history of ischemic heart disease(ex. angina pectoris, myocardial infarction) within the last 3 months
• in investigator's judgement